Physician profile
Kathryn Karhoff
NPI 1972822153
$3,228.91
in general payments reported to CMS, 2019-2025
30 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $404 · 2021: $298 · 2022: $690 · 2023: $613 · 2024: $429 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.79 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.03 | 2021-2025 | |
| Novo Nordisk INC | $545.67 | 2019-2025 | Wegovy, Saxenda |
| Amgen INC. | $289.82 | 2020-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $205.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $158.13 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.94 | 2019-2022 | |
| Abbott Laboratories | $139.36 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $118.59 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.25 | 2021-2024 | Xifaxan |
| Ars Pharmaceuticals Operations, INC. | $103.15 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $91.57 | 2020-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $73.05 | 2024-2025 | Spravato |
| Sanofi Pasteur INC. | $67.01 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $52.66 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.94 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.91 | 2023-2024 | Jardiance, Mounjaro |
| Seqirus USA INC | $36.29 | 2023-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Fluad |
| Novartis Pharmaceuticals Corporation | $30.08 | 2022-2023 | |
| Eisai INC. | $28.91 | 2020 | |
| Merck Sharp & Dohme LLC | $28.85 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.56 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $24.26 | 2021 | |
| Axsome Therapeutics, INC. | $21.20 | 2025 | Auvelity |
| Exact Sciences Corporation | $20.34 | 2023 | Cologuard Collection Kit |
| Biogen, INC. | $19.75 | 2021 | |
| Esperion Therapeutics, INC. | $19.70 | 2021 | |
| Grifols USA, LLC | $18.00 | 2023 | Prolastin-C Liquid |
| Biohaven Pharmaceuticals, INC. | $16.18 | 2021 | |
| Cranial Technologies, INC | $15.77 | 2023 | Doc Band |
| Phadia US INC. | $13.99 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Karhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.